Cargando…

Restricted Mean Survival Time Analysis to Estimate SGLT2i–Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan

IMPORTANCE: Increasing numbers of post hoc analyses have applied restricted mean survival time (RMST) analysis on the aggregated-level data from clinical trials to report treatment effects, but studies that use individual-level claims data are needed to determine the feasibility of RMST analysis for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Zi-Yang, Yang, Chun-Ting, Kuo, Shihchen, Wu, Chih-Hsing, Lin, Wei-Hung, Ou, Huang-Tz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856417/ https://www.ncbi.nlm.nih.gov/pubmed/36520437 http://dx.doi.org/10.1001/jamanetworkopen.2022.46928

Ejemplares similares

Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review
por: Yang, Chun-Ting, et al.
Publicado: (2022)

Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes
por: Yang, Chen-Yi, et al.
Publicado: (2020)

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
por: Yang, Chun-Ting, et al.
Publicado: (2020)

Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
por: Yang, Chen-Yi, et al.
Publicado: (2021)

Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective
por: Su, Hsuan-Yu, et al.
Publicado: (2023)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
por: Hou, Yi-Chou, et al.
Publicado: (2020)

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future
por: Kuo, Shihchen, et al.
Publicado: (2021)

Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study
por: Lin, Fang-Ju, et al.
Publicado: (2021)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
por: Kluger, Aaron Y., et al.
Publicado: (2019)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
por: Salvatore, Teresa, et al.
Publicado: (2022)

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis
por: Chang, Kai-Cheng, et al.
Publicado: (2020)

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
por: Lugner, Moa, et al.
Publicado: (2021)

Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study
por: Peng, Zi-Yang, et al.
Publicado: (2023)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
por: Gao, Yue-Ming, et al.
Publicado: (2022)

Valuing health states of people with type 2 diabetes: Analyses of the nationwide representative linked databases
por: Kuo, Shihchen, et al.
Publicado: (2021)

SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules
por: Wang, Yajiao, et al.
Publicado: (2023)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?
por: Verma, Subodh
Publicado: (2020)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM
por: Li, Lu-Feng, et al.
Publicado: (2021)

Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology
por: Wang, Anzhu, et al.
Publicado: (2022)

SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D
por: Escalada, Javier
Publicado: (2022)

A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
por: Yang, Chun-Ting, et al.
Publicado: (2021)

Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta‐analysis
por: Tian, Qi, et al.
Publicado: (2021)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19
por: Li, Xue-Ting, et al.
Publicado: (2021)

The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
por: Liu, Jiang, et al.
Publicado: (2021)

Three-step matching algorithm to enhance between-group comparability and minimize confounding in comparative effectiveness studies
por: Yang, Chen-Yi, et al.
Publicado: (2022)

SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
por: Lin, Chu, et al.
Publicado: (2021)

Association of ambient air pollution with cardiovascular disease risks in people with type 2 diabetes: a Bayesian spatial survival analysis
por: Su, Pei-Fang, et al.
Publicado: (2020)

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
por: Goncalves, Edison, et al.
Publicado: (2018)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
por: Chen, Hung-Yi, et al.
Publicado: (2020)

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
por: Packer, Milton
Publicado: (2022)

Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice
por: Vergara, Ander, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
por: Srinivas, Natasha, et al.
Publicado: (2021)

Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study
por: Simões de Carvalho, Francisco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pu6ji54pgk56faq991qf4m6bfi